JEJohanna M. Kwakkel-Van Erp

Johanna M. Kwakkel-Van Erp

*This is an algorithmically generated author record based on publicly available information.

Johanna M. Kwakkel-Van Erp has a total of 132 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Considerations for Endpoints in Lung Transplant Clinical Trials: Perspective on the ISHLT Consensus Statement

    by John R. Greenland, Michael Perch, Kieran Halloran, Deborah J. Levine, Eric D. Morrell, Anna Reed, Ciara M. Shaver, Jonathan P. Singer, Stuart C. Sweet, Robin Vos, et al.


  • Top Cited Papers

    Small Airway Disease in Pre-Chronic Obstructive Pulmonary Disease with Emphysema: A Cross-Sectional Study

    by Stijn E. Verleden, Jeroen M. H. Hendriks, Annemiek Snoeckx, Cindy Mai, Yves Mentens, Wim Callebaut, Bruno De Belie, Paul E. Van Schil, Veronique Verplancke, Annelies Janssens, et al.

    Rationale: Small airway disease is an important pathophysiological feature of chronic obstructive pulmonary disease (COPD). Recently, “pre-COPD” has been put forward as a potential precursor stage of COPD that is defined by abnormal spirometry findings or significant emphysema on computed tomography (CT) in the absence of airflow obstruction. Objective: To determine the degree and nature of (small) airway disease in pre-COPD using microCT in a cohort of explant lobes/lungs. Methods: We collected whole lungs/lung lobes from patients with emphysematous pre-COPD (n = 10); Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage I (n = 6), II (n = 6), and III/IV (n = 7) COPD; and controls (n = 10), which were analyzed using CT and microCT. The degree of emphysema and the number and morphology of small airways were compared between groups, and further correlations were investigated with physiologic measures. Airway and parenchymal pathology was also validated with histopathology. Measurements and Main Results: The numbers of transitional bronchioles and terminal bronchioles per milliliter of lung were significantly lower in pre-COPD and GOLD stages I, II, and III/IV COPD compared with controls. In addition, the number of alveolar attachments of the transitional bronchioles and terminal bronchioles was also lower in pre-COPD and all COPD groups compared with controls. We did not find any differences between the pre-COPD and COPD groups in CT or microCT measures. The percentage of emphysema on CT showed the strongest correlation with the number of small airways in the COPD groups. Histopathology showed an increase in the mean chord length and a decrease in alveolar surface density in pre-COPD and all GOLD COPD stages compared with controls. Conclusions: Lungs of patients with emphysematous pre-COPD already show fewer small airways and airway remodeling even in the absence of physiologic airway obstruction.


  • Radiologic and Histologic Correlates of Early Interstitial Lung Changes in Explanted Lungs

    by Stijn E. Verleden, Arno Vanstapel, Joseph Jacob, Tinne Goos, Jeroen Hendriks, Laurens J. Ceulemans, Dirk E. Van Raemdonck, Laurens De Sadeleer, Robin Vos, Johanna M. Kwakkel-Van Erp, et al.

    The histopathologic features of interstitial lung abnormalities included paraseptal organized fibrosis and lymphocytic inflammation that were present in regions considered normal at CT. Background Interstitial lung abnormalities (ILAs) reflect imaging features on lung CT scans that are compatible with (early) interstitial lung disease. Despite accumulating evidence regarding the i...


  • Open Access

    The relation between psychological distress and medication adherence in lung transplant candidates and recipients: A cross‐sectional study

    by Marion J. Wessels‐Bakker, Eduard A. van de Graaf, Johanna M. Kwakkel‐Van Erp, Harry G. Heijerman, Wiepke Cahn, Renske Schappin

    Aims and objectives: To explore the prevalence of psychological distress such as anxiety, depression and post‐traumatic stress disorder and its associations with medication adherence in lung transplant patients.Background: Psychological distress after lung transplantation may impact clinical outcomes by associated behaviours such as non‐adherence to medication. Evidence about the relation between psychological distress and medication adherence in lung transplant patients is limited and not well explained.Design and methods: We conducted a single‐centre study with a cross‐sectional design in 73 lung transplant candidates and 116 recipients. Questionnaires were the Brief Symptom Inventory, Impact of Event Scale and Basel Assessment of Adherence to Immunosuppressive Medications Scale. The STROBE checklist was monitored.Results: In candidates, 39.7% reported (sub)clinical symptoms of depression, in recipients this was 21.6%. We observed suicidal ideation in recipients (8.6%), and candidates (5.5%). The prevalence of (sub)clinical symptoms of anxiety was 38.3% in candidates and 33.7% in recipients. After lung transplantation, 12% of the recipients reported clinical symptoms of PTSD related to the transplantation. Symptoms of anxiety and medication adherence were significantly and positively related in transplant recipients. We found no association between depressive or post‐traumatic stress symptoms, and medication adherence.Conclusions: In lung transplant patients, we found a high prevalence of symptoms of depression and anxiety. Recipients had high levels of post‐traumatic stress symptoms related to the transplantation. The prevalence of suicidal ideation was unexpectedly high in recipients. After lung transplantation, higher levels of anxiety were related to better medication adherence. We propose that LTX recipients are very anxious to develop dyspnoea and therefore take their medication more conscientiously.Relevance to clinical practice: The clinical nurse specialist can play a key role in identifying and addressing psychological and behavioural problems. More prospective research on the role of anxiety and dyspnoea in lung transplant recipients is recommended.


  • Open Access

    Exceptional LAS Requests in Eurotransplant: Analysis of an 8-year Effort to Improve Lung Allocation for Precarious Patients

    by R. Vos, J.M. Smits, R. Hoek, D. Green, P. Evrard, C. Knoop, G.M. Verleden, B. Rondelet, J.M. Kwakkel-Vanerp, L. Seghers, et al.


  • Open Access

    Impact of donor lung quality on post‐transplant recipient outcome in the Lung Allocation Score era in Eurotransplant – a historical prospective study

    by Jacqueline M. Smits, Jens Gottlieb, Erik Verschuuren, Patrick Evrard, Rogier Hoek, Christiane Knoop, György Lang, Johanna M. Kwakkel‐Van Erp, Robin Vos, Geert Verleden, et al.

    The aim of this study was to investigate whether there is an impact of donation rates on the quality of lungs used for transplantation and whether donor lung quality affects post‐transplant outcome in the current LAS era. All consecutive adult LTx performed in Eurotransplant (ET) between January 2012 and December 2016 were included (N=3053). Donors used for LTx in countries with high donation rate were younger (42% vs. 33% ≤ 45 years, p2/FiO2 ≤ 300 mmHg, p<0.0001) and had better lung donor score values (LDS) (28% vs. 17% with LDS=6, p<0.0001) compared to donors used for LTx in countries with low donation rate. Survival rates for the groups LDS =6 and ≥7 at 5 years were 69.7% and 60.9% (p=0.007). Lung donor quality significantly impacts on long‐term patient survival. Countries with a low donation rate are more oriented to using donor lungs with a lesser quality compared to countries with a high donation rate. Instead of further stretching donor eligibility criteria, the full potential of the donor pool should be realized.


  • Open Access

    Effective Prolonged Therapy with Voriconazole in a Lung Transplant Recipient with Spondylodiscitis Induced byScedosporium apiospermum

    by B. Luijk, M. B. Ekkelenkamp, P. A. De Jong, J. M. Kwakkel-Van Erp, J. C. Grutters, D. A. van Kessel, E. A. van de Graaf

    Scedosporium/Pseudallescheriaspecies are frequently seen in cystic fibrosis patients. However, disseminated forms after lung transplantation in these patients are rarely seen, but often with poor outcome. In this case report we describe a lung transplant recipient with cystic fibrosis who developed a spondylodiscitis that was caused byScedosporium apiospermum. The patient was treated with anti-fungal treatment by voriconazole for over three years with a clinical good response and without the need for surgical intervention. To our opinion this is the first anti-fungal treated case of invasive disease caused byScedosporium/Pseudallescheriain a cystic fibrosis (CF) patient who underwent lung transplantation that survived.


  • Bronchovascular Fistula Formation After Lung Transplantation

    by Ed A. van de Graaf, Johanna M. Kwakkel-Van Erp, Diana A. van Kessel, Jules M.M. van Den Bosch, Matthijs F.M. van Oosterhout, Aryan Vink


  • Open Access

    Serum thymus and activation regulated chemokine levels post-lung transplantation as a predictor for the bronchiolitis obliterans syndrome

    by A. W. M. Paantjens, J. M. Kwakkel-Van Erp, W. G. J. Van Ginkel, D A van Kessel, J. M. M. Van Den Bosch, E A van de Graaf, H. G. Otten

    The main reason for mortality after lung transplantation is the bronchiolitis obliterans syndrome (BOS), which represents chronic rejection. As soluble CD30, which is produced mainly by activated T helper 2 (Th2) cells, was shown to be related to development of BOS, we aimed to investigate the relation between development of BOS and Th2 chemoattractant thymus and activation regulated chemokine (TARC/CCL17). In 54 patients we measured serum TARC levels prior to transplantation by enzyme-linked immunosorbent assay, and in 44 of these patients sera were analysed at months 1, 2 and 3 after lung transplantation. In addition, longitudinal measurements were performed in sera from eight healthy controls and 14 patients, the latter taken over a period of 2 years post-transplantation from seven patients developing BOS plus seven clinically matched BOS-free patients. Median serum TARC levels post-transplantation of patients who developed BOS were significantly lower than those of the matched BOS-free patients (P = 0·05). A receiver operating characteristics analysis (area under the curve 0·77), together with a Kaplan–Meyer analysis, showed that serum TARC levels below 325 pg/ml in the first month post-transplantation can predict development of BOS post-transplantation (P = 0·001). In contrast, pretransplant serum TARC levels were not significantly different between patients developing BOS, BOS-free patients or healthy controls. In conclusion, pretransplantation serum TARC levels do not predict the development of BOS post-transplantation, but measurement of the serum TARC levels in the first month directly after transplantation can provide us with a tool to identify the group at risk of developing BOS.